The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.

The award will be presented Oct. 10 during the American Heart Association’s Hypertension Scientific Session in Arlington, Virginia.

As Vanderbilt Health's first Vice President and Chief Advanced Practice Officer, Bennett will provide strategic leadership for the APP community across the enterprise and help shape the future of advanced practice.

"C. diff is one of those infections that turns a routine hospital stay or a course of antibiotics into something far more serious, and older adults bear the brunt of it."

Study provides a unique resource to guide future research on acute rejection diagnosis, therapeutic response prediction, and risk for chronic rejection.

Patients who qualify for new Alzheimer's disease therapies often wait weeks before receiving a first infusion.

Family’s newest commitment will advance research, precision medicine and support services for children with leukemia.